Abstract: Oxidative stress makes up common incidents in
eukaryotic metabolism. The presence of diverse components
disturbing the equilibrium during oxygen metabolism increases
oxidative damage unspecifically in living cells. Body´s own
ubiquinone (Q10) seems to be a promising drug in defending the
heightened appearance of reactive oxygen species (ROS). Though, its
lipophilic properties require a new strategy in drug formulation to
overcome their low bioavailability. Consequently, the manufacture of
heterogeneous nanodispersions is in focus for medical applications.
The composition of conventional nanodispersions is made up of a
drug-consisting core and a surfactive agent, also named as surfactant.
Long-termed encapsulation of the surfactive components into tissues
might be the consequence of the use during medical therapeutics. The
potential of provoking side-effects is given by their nonbiodegradable
properties. Further improvements during fabrication
process use the incorporation of biodegradable components such as
modified γ-polyglutamic acid which decreases the potential of
prospective side-effects.